Zhongqi Dong, Ph.D.
Affiliations: | 2014 | Pharmaceutical Sciences | University of Maryland School of Medicine, Baltimore, MD, United States |
Area:
Pharmacy, Public Health, EpidemiologyGoogle:
"Zhongqi Dong"Cross-listing: PHTree
Parents
Sign in to add mentor| James E. Polli | grad student | 2014 | University of Maryland Medical School | |
| (Inhibitor and Substrate Requirements of Sodium Taurocholate Cotransporting Polypeptide and Its Application to Liver Targeting.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dong Z, Li Q, Guo D, et al. (2015) Synthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the Liver. Journal of Pharmaceutical Sciences |
| Dong Z, Ekins S, Polli JE. (2015) A substrate pharmacophore for the human sodium taurocholate co-transporting polypeptide. International Journal of Pharmaceutics. 478: 88-95 |
| Dong Z, Ekins S, Polli JE. (2014) Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 66: 1-9 |
| Li Q, Guo D, Dong Z, et al. (2013) Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicology and Applied Pharmacology. 273: 100-9 |
| Li Q, Yang H, Peng X, et al. (2013) Ischemia/Reperfusion-inducible protein modulates the function of organic cation transporter 1 and multidrug and toxin extrusion 1. Molecular Pharmaceutics. 10: 2578-87 |
| Dong Z, Ekins S, Polli JE. (2013) Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Molecular Pharmaceutics. 10: 1008-19 |